Effect of ticagrelor sequential therapy after PCI on platelet function and cytokine secretion in patients with ACS

Objective:To explore the effect of ticagrelor sequential therapy after PCI on platelet function and cytokine secretion in patients with ACS.Methods: 176 patients with ACS who underwent PCI in our hospital between January 2015 and January 2018 were divided into the control group (n=92) who received conventional therapy and the ticagrelor group (n=84) who received ticagrelor sequential therapy based on the different therapies after PCI. The differences in serum platelet activation function indexes, myocardial injury indexes and chemokines were compared between the two groups of patients immediately after admission and 1 week after PCI.Results: Immediately after admission, serum platelet activation function indexes, myocardial injury indexes and chemokines were not significantly different between the two groups;1 week after PCI, serum platelet activation function indexes CD62p and CD63 levels of ticagrelor group were lower than those of control group;serum myocardial injury indexes hs-cTnⅠ, IMA, H-FABP and CK-MB contents were lower than those of control group;serum chemokines CXCL16, RANTES and MCP-1 contents were lower than those of control group.Conclusion: ticagrelor sequential therapy after PCI can effectively inhibit the excessive activation of platelets, reduce the postoperative myocardial injury and suppress the systemic inflammatory response in patients with ACS.